期刊文献+

卵巢癌铂类耐药细胞株与敏感株间差异蛋白的筛选 被引量:1

Screening the differential proteins between platinum-resistant and platinum-sensitive cell line of ovarian cancer
原文传递
导出
摘要 目的:筛选卵巢癌铂类耐药细胞和敏感细胞间的差异蛋白质。方法:提取卵巢癌耐卡铂细胞SKOV3/CB和亲本细胞SKOV3的总蛋白,用二维液相色谱技术(ProtemeLabTM PF-2D)分离、筛选差异蛋白,用电喷雾离子化串联质谱(ESI-MS/MS)分析鉴定蛋白质。结果:共分离筛选出差异蛋白54个,其中SK-OV3/CB表达上调的34个,SKOV3表达上调的20个。初步鉴定出5个SKOV3/CB表达上调的差异蛋白,即硫氧还原蛋白(thioredoxin,Trx)、Myosin regulatorylight polypeptide 9(MYL9)、AX887247NID、stanniocalcin homolog、human regu-lator of G-protein signaling 5(RGS-5)。这些蛋白涉及氧化还原、凋亡调控、甲基化及信号传导等多方面。结论:卵巢癌铂类耐药细胞和敏感细胞间存在蛋白表达差异,这些差异蛋白可能通过多种机制介导了卵巢癌对铂类的耐药。 OBJECTIVE:To screen the differential proteins between platinum-resistant and platinum-sensitive cell line of ovarian cancer.METHODS:The total proteins of carboplatin-sensitive(SKOV3) and resistant(SKOV3/CB) human ovarian epithelial cancer cell line were extracted,and the differentially expressed proteins were separated and screened by two-dimensional liquid chromatography.Then the differential proteins were identified by electrospray ionization-tandem mass spectrometry(ESI-MS/MS).RESULTS:A total of 54 differential proteins were isolated and screened,in which 34 proteins were up-regulated in SKOV3/CB and 20 proteins were up-regulated in SKOV3.And 5 differential proteins up-regulated in SKOV3/CB cells were identified and well characterized by bioinformation,including Thioredoxin(Trx),Myosin regulatory light polypeptide 9(MYL9),AX887247 NID,stanniocalcin homolog and human regulator of G-protein signaling 5(RGS-5).These proteins were associated with oxidation and deoxidization,apoptosis,methylation and signal transduction.CONCLUSION:There exists difference in protein expression between platinum-resistant and platinum-sensitive cell line of ovarian cancer,and these differential proteins may induce the platinum resistance in ovarian cancer through the multiple mechanism.
出处 《中华肿瘤防治杂志》 CAS 2011年第22期1765-1769,共5页 Chinese Journal of Cancer Prevention and Treatment
基金 广西自然科学基金资助项目(桂科自0991234) 广西壮族自治区大型仪器协作共用网资助项目
关键词 卵巢肿瘤 抗药性 肿瘤 有机铂化合物 蛋白质阵列分析 二维液相分离 ovarian neoplasms drug resistance neoplasm organoplatinum compounds protein array analysis PF-2D
  • 相关文献

参考文献15

  • 1杨悦.多帕菲联合铂类治疗复发转移性卵巢癌58例临床分析[J].中华肿瘤防治杂志,2008,15(15):1176-1177. 被引量:10
  • 2张飞亚,张美英.卵巢癌细胞减灭术合并回结肠造口的护理[J].护理实践与研究,2010,7(21):62-64. 被引量:1
  • 3栾英姿,李力,黎丹戎,张玮,唐步坚.五种卵巢癌耐药细胞系的建立及其部分耐药相关基因的表达[J].中华妇产科杂志,2004,39(6):403-407. 被引量:21
  • 4Kahlos K,Soini Y,Sily M,et al.Up-regulation of thioredoxinand thioredoxin reductase in human malignant pleural mesotheli-oma[J].Int J Cancer,2001,95(3):198-204.
  • 5Yamada M,Tomida A,Yoshikawa H,et al.Increased expres-sion of thioredoxin/adult T-cell leukemia-derived factor in cispla-tin-resistant human cancer cell lines[J].Clin Cancer Res,1996,2(2):427-432.
  • 6Shao L,Diccianni MB,Tanaka T,et al.Thioredoxin expressionin primary T-cell acute lymphoblastic leukemia and its therapeu-tic implication[J].Cancer Res,2001,61(19):7333-7338.
  • 7Chen XP,Liu S,Tang WX,et al.Nuclear thioredoxin-1is re-quired to suppress cisplatin-mediated apoptosis of MCF-7cells[J].Biochem Biophys Res Commun,2007,361(2):362-366.
  • 8Noguchi S.Predictive factors for response to docetaxel in humanbreast cancers[J].Cancer Sci,2006,97(9):813-820.
  • 9Yamada M,Tomida A,Yoshikawa H,et al.Overexpression ofthioredoxin does not confer resistance to cisplatin in transfectedhuman ovarian and colon cancer cell lines[J].Cancer ChemotherPharmacol,1997,40(1):31-37.
  • 10Sun L,Gorospe JR,Hoffman EP,et al.Decreased platelet ex-pression of myosin regulatory light chain polypeptide(MYL9)and other genes with platelet dysfunction and CBFA2/RUNX1mutation:insights from platelet expression profiling[J].JThromb Haemost,2007,5(1):146-154.

二级参考文献32

  • 1赵彦,钱和年,崔恒,王杉,李蔚范,顾晋.18例妇科恶性肿瘤结肠、直肠手术临床分析[J].中国妇产科临床杂志,2001,2(4):200-202. 被引量:1
  • 2梁秀琼.肠造口术的护理进展[J].护理学杂志(外科版),2005,20(7):79-80. 被引量:32
  • 3刘军.艾素联合异环磷酰胺治疗复发性卵巢上皮癌近期疗效观察[J].中国肿瘤临床与康复,2005,12(5):417-418. 被引量:1
  • 4Webb BL, Lindsay MA, Seybold J, et al. Identification of the protein kinase C isoenzymes in human lung and airways ooth muscle at the protein and mRNA level.Biochem Pharmacol, 1997,54:199-205.
  • 5Withoff S, van der Zee AG, de Jong S, et al. DNA topoisomerase IIalpha and -beta expression in human ovarian cancer.Br J Cancer,1999,79:748-753.
  • 6Fajac A, Da Silva J, Ahomadegbe JC, et al. Cisplatin-induced apoptosis and p53 gene status in a cisplatin-resistant human ovarian carcinoma cell line.Int J Cancer,1996,68:67-74.
  • 7Satoh T, Nishida M, Tsunoda H, et al. Expression of glutathione S-transferase pi (GST-pi) in human malignant ovarian tumors.Eur J Obstet Gynecol Reprod Biol, 2001,96:202-208.
  • 8Hill BT, Moran E, Etievant C, et al. Low-dose twice-daily fractionated X-irradiation of ovarian tumor cells in vitro generates drug-resistant cells overexpressing two multidrug resistance-associated proteins, P-glycoprotein and MRP1.Anticancer Drugs,2000,
  • 9Cvitkovic E. Ongoing and unsaid on oxaliplatin: the hope.Br J Cancer,1998,77 Suppl 4:8-11.
  • 10Perego P, Giarola M, Righetti SC, et al. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.Cancer Res, 1996,56:556-562.

共引文献29

同被引文献11

  • 1Diaz-montes TP, Bristow RE. Secondary cytoreduction for pa- tients with recurrent ovarian cancer [J]. Curr Oncol Rep, 2005,7 (6) :451-458.
  • 2Grade M, Hummon AB, Camps J, et al. A genomic strategy for the functional validation of colorectal cancer genes identifies po- tential therapeutic targets[J]. Int J Cancer, 2011,128(5) : 1069- 1079.
  • 3Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C (T)) method[J]. Methods,2001,25(4) :402-408.
  • 4Bookman MA. Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinie[J]. Int J Gynecol Cancer, 2005,15(Suppl I) : 12-17.
  • 5Smith BD,Karp JE. Ribonucleotide reductase: an old target with new potential[J]. Leuk Res,2003,27(12) : 1075-1076.
  • 6Duxbury MS, Ito H, Benoit E, et al. Retrovirlly mediated RNA interference targeting the M2 subunit of ribonueleotide reduc- tase:a novel therapeutic strategy in pancreatic cancer[J]. Surger- y, 2004,136 (2) : 261-269.
  • 7Burton TR, Kashour T, WrJight J A, et al. Cellular signaling pathways affect the function of ribonuleotie reductase mRNA binding proteins: mRNAs tabilization,drug resistance,and malignancy (Review) [J]. Int J Oncoi,2003,22(1) :21-31.
  • 8Xu X, Page JL, Suttees JA, et al. Broad overexpression of ribonue- leotide reductase genes in mice specifically induces lung neoplasms [J]. Cancer Res,2008,68(8) :2652-2660.
  • 9Wang X, Zhenchuk A, Wiman KG, et al. Regulation of p53 R2 and its role as potential target for cancer therapy [J]. Cancer Lett,2009,276(1) : 1-7.
  • 10卢飞飞,任婧婧,王黎明,孙显璐.上皮性卵巢癌组织RRM1和RRM2表达及其意义[J].齐鲁医学杂志,2011,26(5):393-395. 被引量:1

引证文献1

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部